John Hancock U.S. Growth Fund's Q1 2026 Performance and Economic Outlook
Finance

John Hancock U.S. Growth Fund's Q1 2026 Performance and Economic Outlook

authorBy Robert Kiyosaki
DateJun 19, 2026
Read time2 min

In the initial quarter of 2026, the John Hancock U.S. Growth Fund (JSGAX) demonstrated a marginal lag against the broader Russell 1000 Growth Index. This performance was influenced by specific stock choices, particularly in the consumer discretionary and healthcare sectors, which negatively impacted overall returns. Conversely, strategic investments in the information technology (IT) sector and an intentional overweight position in energy stocks offered positive contributions, partially mitigating the drag from other areas.

The fund's strategic allocation emphasizes growth and valuation upside, with a substantial portion of its assets (30% each) dedicated to these factors. Simultaneously, it maintains an underweight stance in total capital return and quality, with each representing 20% of the portfolio. This positioning reflects a deliberate focus on high-quality, resilient growth companies, aligning with the management's view on the evolving economic landscape.

Looking forward, with various key economic indicators showing signs of improvement and pointing towards potential acceleration, the fund managers are proactively adjusting the portfolio. The aim is to capitalize on an anticipated upturn in economic activity, emphasizing companies expected to thrive in a more dynamic market environment. The fund's commitment to high-quality, durable growth remains a cornerstone of its investment philosophy, designed to navigate market fluctuations and capture long-term appreciation.

The proactive adjustment of the fund's holdings to align with a scenario of continued economic growth underscores a forward-thinking investment approach. By selectively emphasizing sectors and companies poised for expansion, the fund seeks to deliver sustained value for its investors. This strategic foresight is crucial in today's dynamic market, guiding the fund toward opportunities that promise robust returns while upholding a commitment to sound investment principles.

More Articles
Finance
Alphabet's Cloud Triumph and AI-Driven Growth: A Discrepancy in Stock Performance
Google Cloud's exceptional revenue and margin expansion, surpassing key rivals AWS and Azure, signals a robust growth trajectory, underscored by a significant backlog into 2026. Coupled with consistent acceleration in Google Search revenue due to enhanced AI monetization in advertising, Alphabet showcases strong operational performance. Despite these achievements, its stock underperforms the Nasdaq, suggesting an undervalued asset. The company's strategic, elevated capital expenditure for 2026 and a positive outlook for 2027 further support future cloud growth, indicating demand continues to exceed current capacity. This strong AI integration and financial health advocate for a re-evaluation of Alphabet's market premium.
By Fareed ZakariaJun 19, 2026
Finance
KBR Inc. Undervalued: Discerning Value in its Dual Business Structure
KBR Inc. (KBR) is currently undervalued due to market misperception, failing to differentiate its two distinct business segments: Mission Technology (MTS) and Science and Technology (STS). MTS provides extensive scale and backlog with moderate margins, while STS offers superior margins and profitability, necessitating separate valuation models. A sum-of-the-parts analysis projects a base-case valuation of $59 per share, indicating a potential 69% upside, with more aggressive scenarios reaching $71–$88 per share.
By Strive MasiyiwaJun 19, 2026
Finance
BMW's Challenging Road Ahead: Navigating China's Market and Cost Pressures
BMW has revised its 2026 financial outlook, projecting automotive EBIT margins of 1-3% and reduced deliveries, primarily due to struggles in the Chinese market. The first quarter saw an 8.1% revenue decline and a 36.2% drop in EBIT, with China's deliveries falling 10% despite the company gaining market share. Aggressive cost management, including an 11.5% reduction in R&D and a 5.1% cut in SG&A, is underway to counter margin erosion and falling free cash flow yields. Given these factors, the stock is currently rated as 'Hold', as its valuation appears fair with limited immediate growth prospects.
By Lisa JingJun 19, 2026
Finance
Tarsus Pharmaceuticals: XDEMVY's Strong Market Penetration Drives 'Buy' Rating
Tarsus Pharmaceuticals' XDEMVY is rapidly dominating the Demodex blepharitis market, supporting its 'Buy' rating. The company boasts an impressive 85% year-over-year sales growth and approximately 93% gross margin. With XDEMVY as the sole FDA-approved treatment and patent protection until 2038, its sustained growth is crucial for valuation, justifying significant investment if operational efficiency improves with scaling sales.
By Nouriel RoubiniJun 19, 2026
Finance
Fidelity Corporate Bond Fund's Q1 2026 Performance and Market Dynamics
The Fidelity Corporate Bond Fund recorded a -0.55% return in the first quarter of 2026, slightly underperforming its benchmark, the Bloomberg U.S. Credit Bond Index, which posted -0.48%. The fund significantly increased its holdings in major tech companies like Alphabet, Meta Platforms, and Oracle, marking a new strategic direction towards AI-related sectors. This report details the fund's asset allocation decisions, including its neutral stance on banks, overweight positions in insurers and REITs, and the reduction of U.S. Treasuries and cash for liquidity and risk management. Security selection in financials, particularly underweighting certain banks, positively impacted performance.
By Suze OrmanJun 19, 2026